Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Year in Review
NSCLC IO 2022 - Midyear Review
NSCLC IO 2022 - Midyear Review
Year in Review
Real-World Effectiveness of Immune Checkpoint Inhibitors with or without Chemotherapy in Metastatic NSCLC
NSCLC IO 2022 - Midyear Review
In real-world practice, the combination of immune checkpoint inhibitors with chemotherapy in patients with metastatic NSCLC may delay progression compared with immune checkpoint inhibitors alone but does not affect long-term outcomes.
Read More ›
Year in Review
CTLA-4 Single-Nucleotide Polymorphism Is Associated with High Response to Anti–PD-1/PD-L1 Immunotherapy in Advanced NSCLC
NSCLC IO 2022 - Midyear Review
A noncoding single-nucleotide polymorphism in the CTLA-4 gene was found to be common among responders to anti–PD-1/PD-L1 therapies, which may enhance the clinical effect of PD-1 blockade.
Read More ›
Year in Review
ATM Mutations in NSCLC Define Patients with Distinct Clinicopathologic, Genomic, and Immunophenotypic Characteristics
NSCLC IO 2022 - Midyear Review
Mutations in the
ATM
gene, the most mutated DNA damage and repair gene in cancer, were found to define distinct subsets of patients with NSCLC with unique genomic characteristics, clinicopathologic features, and sensitivity to chemoimmunotherapy.
Read More ›
Year in Review
A Phase 3 Study of First-Line Sugemalimab versus Placebo plus Platinum-Based Chemotherapy for Patients with Metastatic NSCLC: GEMSTONE-302
NSCLC IO 2022 - Midyear Review
Sugemalimab plus chemotherapy resulted in statistically significant and clinically meaningful progression-free survival and overall survival improvement compared with placebo plus chemotherapy, regardless of tumor histology or PD-L1 expression level, in patients with newly diagnosed metastatic NSCLC.
Read More ›
Year in Review
Toripalimab versus Placebo in Combination with First-Line Chemotherapy for Advanced NSCLC without EGFR/ALK Mutations: CHOICE-01 Phase 3 Study
NSCLC IO 2022 - Midyear Review
First-line treatment of patients with advanced NSCLC with toripalimab plus chemotherapy resulted in improved progression-free survival and overall survival compared with chemotherapy alone.
Read More ›
Year in Review
Nivolumab with or without Docetaxel for Patients with Previously Treated Advanced or Recurrent NSCLC: Results from the Phase 2/3 TORG1630 Trial
NSCLC IO 2022 - Midyear Review
The combination of nivolumab plus docetaxel for NSCLC in the second-line setting improved overall survival, progression-free survival, and overall response rate, despite a slightly elevated risk of toxicity.
Read More ›
Year in Review
Canakinumab Combined with First-Line Pembrolizumab and Chemotherapy for Advanced NSCLC: CANOPY-1
NSCLC IO 2022 - Midyear Review
The combination of canakinumab and pembrolizumab plus chemotherapy did not statistically improve efficacy as first-line treatment in patients with advanced NSCLC.
Read More ›
Year in Review
Neoadjuvant Durvalumab Alone or Combined with Novel Agents for Resectable, Early-Stage NSCLC: NeoCOAST Trial
NSCLC IO 2022 - Midyear Review
Neoadjuvant treatment of patients with resectable early-stage NSCLC with durvalumab in combination with the anti-CD73 monoclonal antibody oleclumab, the anti-NKG2A monoclonal antibody monalizumab, or the anti-STAT3 antisense oligonucleotide danvatirsen resulted in improved efficacy compared with durvalumab alone.
Read More ›
Year in Review
Neoadjuvant Nivolumab and Platinum-Doublet Chemotherapy for Resectable NSCLC: CheckMate 816
NSCLC IO 2022 - Midyear Review
Neoadjuvant nivolumab plus platinum-doublet chemotherapy resulted in clinically meaningful improvement in event-free survival and pathologic complete response in patients with resectable NSCLC compared with chemotherapy alone.
Read More ›
Year in Review
First-Line Nivolumab plus Ipilimumab in Combination with Chemotherapy versus Chemotherapy Alone in Patients with Metastatic NSCLC: 3-Year Update from CheckMate 9LA
NSCLC IO 2022 - Midyear Review
The 3-year extended follow-up of CheckMate 9LA demonstrated that first-line nivolumab plus ipilimumab in combination with limited chemotherapy resulted in long-term, durable clinical benefit compared with chemotherapy alone in patients with metastatic NSCLC, regardless of PD-L1 mutation status.
Read More ›
Page 2 of 3
1
2
3
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us